JV

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

Retrieved on: 
Tuesday, November 28, 2023

The new JV will be located in Riyadh, Saudi Arabia, and operate under the name ‘Lifera Omics’.

Key Points: 
  • The new JV will be located in Riyadh, Saudi Arabia, and operate under the name ‘Lifera Omics’.
  • Lifera Omics will build on this strength with an advanced laboratory and bioinformatics infrastructure, also leveraging the CENTOGENE Biodatabank.
  • In addition, Lifera made an investment in CENTOGENE in the form of a mandatorily convertible loan with a total aggregate principal amount of $30 million.
  • CENTOGENE and Lifera management will be presenting at the Global Healthspan Summit at the Four Seasons Hotel in Riyadh on November 30, 2023.

ROCKLEY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Rockley Photonics Holdings Limited and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, November 26, 2023

Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Rockley specializes in the research and development of integrated silicon photonics chipsets and modules for sensory and communications products.
  • There is no cost or obligation to you.

ROCKLEY ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rockley To Contact Him Directly To Discuss Their Options

Retrieved on: 
Sunday, November 26, 2023

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rockley Photonics Holdings Limited (“Rockley” or the “Company”) (NYSE: RKLY) and reminds investors of the January 8, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Rockley’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

STEALTHGAS INC. Reports Third Quarter and Nine Months 2023 Financial and Operating Results

Retrieved on: 
Tuesday, November 21, 2023

Voyage expenses and vessels’ operating expenses for the three months ended September 30, 2023 were $2.4 million and $12.3 million, respectively, compared to $6.8 million and $14.1 million, respectively, for the three months ended September 30, 2022.

Key Points: 
  • Voyage expenses and vessels’ operating expenses for the three months ended September 30, 2023 were $2.4 million and $12.3 million, respectively, compared to $6.8 million and $14.1 million, respectively, for the three months ended September 30, 2022.
  • Drydocking costs for the three months ended September 30, 2023 and 2022 were $0.1 million and $1.8 million, respectively.
  • Management fees for the three months ended September 30, 2023 and 2022 were $1.1 million and $1.3 million, respectively.
  • General and administrative expenses for the three months ended September 30, 2023 and 2022 were $1.7 million and $0.8 million, respectively.

ROCKLEY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Rockley Photonics Holdings Limited and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, November 21, 2023

Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Rockley specializes in the research and development of integrated silicon photonics chipsets and modules for sensory and communications products.
  • There is no cost or obligation to you.

enCore Energy Provides 2023 Year End Letter

Retrieved on: 
Friday, December 22, 2023

DALLAS, Texas, Dec. 22, 2023 /PRNewswire/ - enCore Energy Corp. ("enCore" or the "Company") (NYSE American: EU) (TSXV: EU) today provides the Company's Year End Letter thanking shareholders for their support through a transformational year at America's Clean Energy Company™.

Key Points: 
  • DALLAS, Texas, Dec. 22, 2023 /PRNewswire/ - enCore Energy Corp. ("enCore" or the "Company") (NYSE American: EU) (TSXV: EU) today provides the Company's Year End Letter thanking shareholders for their support through a transformational year at America's Clean Energy Company™.
  • With a clear path towards our objective to be a domestic uranium producer in the United States, enCore achieved a successful 2023.
  • We see the shift towards nuclear energy as a power source, increasing the need for uranium, as a multi-decade cycle.
  • Thank you again from enCore Energy, America's Clean Energy Company™.

RKLY INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Securities Class Action Lawsuit Against SC Health Holdings Limited and Announces Opportunity for Investors with Substantial Losses to Lead the Rockley Class Action Lawsuit

Retrieved on: 
Sunday, November 19, 2023

), the Rockley class action lawsuit charges SC Health Holdings Limited, SC Health Group Limited, SIN Capital Group Pte.

Key Points: 
  • ), the Rockley class action lawsuit charges SC Health Holdings Limited, SC Health Group Limited, SIN Capital Group Pte.
  • A lead plaintiff acts on behalf of all other class members in directing the Rockley class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Rockley class action lawsuit.
  • An investor’s ability to share in any potential future recovery of the Rockley class action lawsuit is not dependent upon serving as lead plaintiff.

ROCKLEY ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rockley To Contact Him Directly To Discuss Their Options

Retrieved on: 
Sunday, November 19, 2023

NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rockley Photonics Holdings Limited (“Rockley” or the “Company”) (NYSE: RKLY) and reminds investors of the January 8, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Rockley’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results

Retrieved on: 
Wednesday, November 15, 2023

AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).

Key Points: 
  • AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).
  • The financial results are based on the Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 14, 2023.
  • Highlights for Q3 2023 and thereafter:
    We have been enjoying the effects of the benefits of the JV transaction, between Dragon Overseas Limited (“Dragon”) and us, through the formation of GMP Biotechnology Limited (“GMP Bio” or “JV”) being reflected in our financial results.
  • “Commencing April 2022, with the culmination of the JV with Dragon, and continuing into 2023 till date, have been a good eighteen months for us.

ArcelorMittal S.A.: ArcelorMittal enters the additive manufacturing industry as a steel powder supplier

Retrieved on: 
Wednesday, November 15, 2023

ArcelorMittal today announces its entry into the additive manufacturing (AdM) market as a steel powder supplier.

Key Points: 
  • ArcelorMittal today announces its entry into the additive manufacturing (AdM) market as a steel powder supplier.
  • This will enable ArcelorMittal to supply significant volumes of steel powders with consistent quality, reliability and traceability, meeting the high standards and specifications of the AdM industry.
  • In line with ArcelorMittal's commitment to sustainability and decarbonisation, the company is committed to advancing the sustainability of additive manufacturing.
  • By producing and supplying steel powders for additive manufacturing, we are expanding our portfolio of advanced materials and solutions for the future of manufacturing.